🚨New online!

🤔Could gut-targeted immune therapy, such as #vedolizumab, reduce the risk of #MultipleSclerosis?

📊Afsaneh Shirani and Olaf Stuve analyzed health records of over 2 million people to investigate the role of T cell licensing pathways in MS:
journals.sagepub.com/doi/full/10....

IV vs SC Vedolizumab for IBD | Docwire News While intravenous and subcutaneous vedolizumab had largely similar safety and efficacy for IBD, there were a few key differences in outcomes.

Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally Halozyme and Takeda have signed an exclusive global deal to enhance the delivery of vedolizumab, leveraging Halozyme's innovative ENHANZE technology for better patient outcomes.

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally #United_States #San_Diego #Halozyme #ENHANZE #Vedolizumab

Vedolizumab shows potential for ICI therapy-induced colitis Upfront vedolizumab treatment for ICI-induced colitis may reduce the burden of corticosteroid therapy and enable a faster return to cancer therapy.

From #UEGWeek 2025 - Upfront #vedolizumab treatment for #ICI-induced colitis may reduce the burden of corticosteroid therapy and enable a faster return to cancer therapy.

Full story 👉 buff.ly/Eixl7gj

#MedNews

#biosimilars #PolpharmaBiologics #MSPharma #gastroenterology #neurology #dermatology #MENA #vedolizumab #ocrelizumab #guselkumab #ulcerativecolitis #Crohnsdisease #multiplesclerosis #plaquepsoriasis #psoriaticarthritis #biosimilarmanufacturing #MS #PolpharmaBiologicsGroup
zurl.co/GJnQQ

Clinical use of vedolizumab subcutaneous formulation in inflammatory bowel diseases: a review of real-world evidence Vedolizumab SC gives patients with ulcerative colitis and Crohn’s disease an alternative administration route during maintenance treatment, but how effective and safe is it in clinical practice under…

#Vedolizumab SC gives patients with #UlcerativeColitis and #CrohnsDisease an alternative administration route during maintenance treatment, but how effective and safe is it in clinical practice under real-world conditions?

👉 buff.ly/u5Z9qQ1

#GastroSky #MedSky

Any idea if severe repeated episodes of hypoglycemia in a diabetic patient with ulcerative colitis could be a side effect of Vedolizumab? #ulcerativecolitis #vedolizumab #Entyvio #diabetes

Redirecting

Happy to share the work from my residency at #Charite available as pre-proof version in #Gastroenterology.

We identify Ki67+ memory CD4+ T cells as robust blood-based predictor for non-response to #vedolizumab (anti-integrin a4b7) in #IBD patients before therapy.

doi.org/10.1053/j.ga...